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Overview. The GiACTA trial is a multicenter, randomized, double-blind, and placebo-controlled study designed to test the ability
of tocilizumab (TCZ), an interleukin (IL)-6 receptor antagonist, to maintain disease remission in patients with giant cell arteritis
(GCA). Design. Approximately 100 centers will enroll 250 patients with active disease. The trial consists of a 52-week blinded
treatment phase followed by 104 weeks of open-label extension. Patients will be randomized into one of four groups. Group A
(TCZ162mgweeklyplusa6-monthprednisone-taper);groupB(TCZ162mgeveryotherweek plusa6-monthprednisone-taper);
group C (placebo plus a 6-month prednisone-taper); and group D (placebo plus a 12-month prednisone taper). We hypothesize
that patients assigned to TCZ in addition to a 6-month prednisone course are more likely to achieve the primary efficacy endpoint
of sustained remission (SR) at 52 weeks compared with those assigned to a 6-month prednisone course alone, thus potentially
minimizing the long-term adverse effects of corticosteroids. Conclusion. GiACTA will test the hypothesis that interference with
IL-6 signaling exerts a beneficial effect on patients with GCA. The objective of this paper is to describe the design of the trial and
address major issues related to its development.
1. Introduction
Giant cell arteritis (GCA, temporal arteritis) is an inflam-
matory disease of medium- and large-sized arteries that
affects individuals older than 50 years of age [1]. The dis-
ease commonly involves the aorta, great vessels, and the
extracranialbranchesofthecarotidarteries.GCAisthemost
common primary form of vasculitis in Western countries
and has a prevalence that ranges from 24 to 280 cases per
100,000 in individuals older than 50 years [2–4]. Its clinical
presentationconsistsofconstitutionalsymptoms,headaches,
ischemia-related visual manifestations, jaw claudication, and
polymyalgia rheumatica. The inflammatory markers (ery-
throcyte sedimentation rate [ESR] and C-reactive protein
[CRP]) are elevated in the vast majority of the cases during
active disease [5].
GCAanditscurrenttreatmentstrategiescarryasubstan-
tial morbidity burden. The most feared consequence of the
diseaseisblindness[6],butmultiplecomplicationscanensue
(e.g., tonguenecrosis,aorticaneurysm,stroke,ormyocardial
infarction). Corticosteroids (CS), the mainstay of treatment,
control systemic inflammation effectively and prevent acute
damage (i.e., vision loss) but generally fail to cure GCA or
induce long-term CS-free remissions. Fifty to 80% of the
patients relapse upon dose reduction and therefore require
long-term treatment courses that are associated with toxicity
in nearly all cases (i.e., hypertension, infection, fragility
fractures, cataracts, gastrointestinal bleeding, weight gain,
diabetes mellitus, and psychosis) [7, 8].
Attempts to control disease activity and spare CS with
other agents have generally failed [9–11]. Trials using
methotrexate (MTX) have produced conflicting results [12–
14], and studies of tumor necrosis factor inhibitors have
been negative [15, 16]. Thus, an agent capable of maintaining
disease remission after the discontinuation of high-dose CS2 International Journal of Rheumatology
is still lacking. Based on results from the open-label use of
the IL-6R antagonist tocilizumab (TCZ, Actemra; Roche)
for the treatment of GCA [17–25] and data generated in
TCZ trials for rheumatoid arthritis (RA) [26–29], a phase
IIIrandomized,double-blind,andplacebo-controlledtrialof
TCZ for GCA has been initiated. The objectives of this paper
are to describe the design elements of the GiACTA trial and
to discuss issues related to the development of the study.
2. Design and Methods
2.1. Rationale for Using IL-6 Blockade in GCA. The cellular
b r a n c ho ft h ea d a p t i v ea n di n n a t ei m m u n es y s t e m sa p p e a r s
to be central to the pathogenesis of GCA, even though the
antigen(s) that trigger the disease remain unknown [30, 31].
In untreated patients, an expanded repertoire of autoreactive
CD4-positive T lymphocytes, including IFN-𝗾 producing T
helper (Th) 1 cells and IL-17-secreting Th17 cells, orchestrates
the formation of granulomatous vascular inflammation [32–
35]. In contrast, the number of Foxp3+ regulatory T cells
(Treg), which normally serve to limit immune responses, is
decreased [33, 35].
IL-6 is a pleiotropic cytokine produced by T cells, B
cells, macrophages, endothelial cells, and fibroblasts upon
different stimuli [36]. Under physiologic conditions, IL-6
triggers the synthesis of acute phase proteins, promotes the
transitionfromacutetochronicinflammation,andfacilitates
the development of specific immunity. IL-6 participates in
the activation of T cells, the terminal differentiation of B
cells, the survival of plasmocytes, the differentiation of Th17
lymphocytes [37], the inhibition of Treg-cell differentiation
and function [38], and the induction of a proinflammatory
phenotypeamongmonocytes/macrophages,endothelial,and
stromal cells. Thus, the IL-6 pathway is located at the
intersection of the innate and acquired immunesystems and,
if dysregulated, has the potential to perpetuate inflammatory
responses.
In GCA patients, IL-6 is up regulated within inflamed
arteries [39–41], and its concentration in the peripheral cir-
culationiselevated[42, 43]. Serum IL-6 levels mirror disease
activity and decline with adequate CS treatment [44, 45]. We
speculate that IL-6R blockade with tocilizumab may amelio-
rate vascular inflammation through several mechanisms: (a)
alteringupstreamdifferentiationofautoreactivelymphocytes
[46–48]; (b) promoting the generation of Treg cells [49];
and (c) targeting downstream aspects of the inflammatory
cascade [40].
In published reports, approximately two dozens of
patients with GCA have received TCZ [17–25]. Patients
responded well, and no limiting safety concerns were noted.
InGCApatients,pre-andpostdoseCRPlevelsweresimilarto
thoseseeninRA,andthenormalizationofthisinflammatory
parameter was sustained.
2.2. Study Design. GiACTA is designed to evaluate the safety
a n de ffi c a c yo fT C Zf o rt h et r e a t m e n to fG C A .T w oh u n d r e d
a n dfi ft y( 2 5 0 )p a t i e n t sw i l lb ee n r o l l e da n da s s i g n e dt oo n e
of four treatment arms. The trial will consist of a 52-week
blinded period (Part 1), followed by a 104-week open-label
extension (Part 2) (Figure 1).
Two subcutaneous (SC) doses of TCZ (162 mg every
week [162qw] and 162mg every other week [162q2w]) will be
comparedtoplacebo.AllpatientswillreceivebackgroundCS
therapy. Three groups (A, B, and C) will follow a prespecified
prednisone-taper regimen over 26 weeks, and a fourth group
(group D), designed to reflect an alternate standard of care,
will receive a 52-week prednisone taper (see Figure 1 and
Section 2.8).
The primary efficacy endpoint, sustained remission (SR),
will be evaluated at 52 weeks. Remission is defined as the
absence of signs and symptoms attributable to GCA and
normalization of ESR (<30mm/Hr) and CRP (<1mg/ dL).
Other definitions used in the trial are described in Table 1.
The purpose of Part 2 is to determine the long-term
safetyandmaintenanceefficacyofTCZ,toexploreapotential
requirement for maintenance treatment beyond 52 weeks,
a n dt og a i ni n s i g h ti n t ot h el o n g - t e r mC S - s p a r i n ge ff e c to f
IL-6R blockade. Those who achieve the primary endpoint
will stop their blinded SC injections and be followed for
maintenance of response. Patients with persistent disease
activityorthosewhoexperienceaflareafterweek52willhave
the option to receive open-label TCZ (162mg weekly) with
or without increase in background CS dose at the discretion
of the investigator. The duration of open-label therapy will
be determined by the investigator according to the patient’s
clinical condition.
2.3. Organization and Funding. The GiACTA research group
comprises100sitesintheUSAandEurope.Thetrialisfunded
by F. Hoffmann-La Roche, Ltd (Switzerland). Mechanistic
studies are supported in part through a grant from the
Arthritis Foundation.
2.4. Institutional Review Board Approval and Informed Con-
sent. Each participating clinic will have institutional review
board oversight. All participants will give written informed
consent.
2.5. Trial Objectives and Hypothesis. The primary objective
of GiACTA is to evaluate the efficacy of TCZ in combination
with a six-month prednisone taper to sustain remission
through 52 weeks. To meet this endpoint, a patient must
maintaindiseaseremissionafterremissioninductionbyweek
12ofrandomization,completetheassignedprednisone-taper
protocol, and not flare or require escape therapy at any time
until week 52.
The primary efficacy analysis will compare groups A and
B against group C (see Section 2.7). We hypothesize that
patientsassignedtoTCZinadditiontoa26-weekprednisone
course are more likely to achieve SR at 52 weeks compared
with those assigned to a 26-week prednisone course alone,
thus potentially minimizing the long-term adverse effects of
CS.
Secondary and exploratory objectives of the trial are to
evaluate safety, the impact of TCZ on cumulative CS expo-
sure, long-term remission maintenance beyond 52 weeks,International Journal of Rheumatology 3
52-week double blind (part 1) 104-week open-label extension (part 2)
TCZ 162 weekly
Prednisone
Prednisone
Prednisone
Prednisone
Prednisone
𝑛 = 100
𝑛=5 0
𝑛=5 0
𝑛=5 0
Screen
(42 days)
Baseline (BS)
randomization
Patients in remission at 52 weeks
Long-term followup off the study drug
Patients with disease activity or ﬂare
Open-label TCZ 162 mg weekly
Primary efficacy endpoint:
sustained remission at 52 weeks
CS
MTX (if required)
60–20 mg by BS
Escape CS permitted
Patients stay in part 1
MTX; stable, reduced, or discontinued 
CS use at the investigator’s discretion
MTX initiation is allowed
TCZ 162 mg every 2 weeks
Figure 1: Study schema.
patient-reported outcomes, and to compare the TCZ arms
against the 52-week prednisone taper. Pharmacokinetic-
pharmacodynamic(PK-PD)studies,immunogenicityassays,
and mechanistic investigations will also be performed.
2.6. Eligibility Criteria and Assessment of Disease Activ-
ity. The eligibility criteria for the trial are summarized in
Table 2.P a t i e n t sw i l lb er e q u i r e dt oh a v ea c t i v ed i s e a s e
within 6 weeks prior to the baseline visit. New onset and
relapsed/refractory GCA patients will be eligible. The num-
ber of relapsed/refractory subjects will be capped at 70%.
Active disease for enrollment is defined as the presence of
unequivocalclinicalsignsandsymptomsattributabletoGCA
and increased levels of circulating inflammatory markers
(ESR ≥30mm/hr and/or CRP ≥1mg/dL). All patients will
receivebackgroundprednisonetherapyandfollowaprespec-
ified tapering protocol (see Table 3 and Section 2.8).
2.7. Assignment to Study Groups. Two hundred and fifty
patients will be randomized through an interactive voice
responsesystem(IVRS)ina2:1:1:1ratiotothedifferent
s t u d ya r m sa sf o l l o w s( Figure 1):
(A) TCZ 162qw + 26 weeks of prednisone + 26 weeks of
prednisone placebo (𝑛 = 100);
( B )T C Z1 6 2 q 2 w+2 6w e e k so fp r e d n i s o n e+2 6w e e k so f
prednisone placebo (𝑛=5 0 );
(C) TCZ-placebo + 26 weeks of prednisone+ 26 weeks of
prednisone placebo (𝑛=5 0 ); and
(D) TCZ-placebo + 52 weeks of prednisone (𝑛=5 0 ).
To ensure balance across groups, the randomization will
be stratified by baseline prednisone dose (<30mg/day or
≥30mg/day)andwhetherthepatientspresentwithnewonset
or refractory/relapsed disease.
SubjectswillreceiveeitherTCZormatchingTCZplacebo
by SC injection once a week. The dose modification guide-
lines and risk mitigation strategy used for TCZ in RA will
be implemented in GIACTA (Actemra [tocilizumab] US
Package Insert, RoActemra [tocilizumab] European Union
Summary of Product). Measures designed to protect against
unblinding are addressed in the Discussion section.
2.8. Prednisone Regimens
2.8.1. Assignment of the Initial Prednisone Dose. The inves-
tigator will determine the initial prednisone dose from the
timeofenrollmentbasedonthediseasehistory(newonsetor
refractory/relapsing disease), severity of activity (e.g., visual
symptoms), and comorbidities (e.g., diabetes mellitus). By
definition, patients with refractory/relapsing GCA will have
active disease despite previous or concurrent CS therapy. In
the last case, an increase in CS dose will be required upon
enrollment.Permittedrangesofstartingdosesforanypatient
will be 20–60mg daily. From the dose chosen at baseline,
the patients will proceed with a protocol-defined tapering
schedule depending on the group assigned (Table 3). “Pulse”
intravenous doses of glucocorticoids defined as methylpred-
nisolone >100mg/day will not be permitted if given within 6
weeks prior to enrollment.4 International Journal of Rheumatology
Table 1: Critical trial definitions.
Term Definition
Revised GCA diagnosis criteria
(1) Age ≥50 years
(2) History of ESR ≥50 mm/hour
(3) And at least one of the following:
(a) Unequivocal cranial symptoms of GCA (new onset localized headache, scalp or temporal artery
tenderness, ischemia-related vision loss, or otherwise unexplained mouth or jaw pain upon
mastication)
(b) Unequivocal symptoms of polymyalgia rheumatica (PMR), defined as shoulder and/or hip girdle
pain associated with inflammatory stiffness
(4) And at least one of the following:
(a) Temporal artery biopsy revealing features of GCA
(b) Evidence of large-vessel vasculitis by angiography or cross-sectional imaging study such as
magnetic resonance angiography (MRA), computed tomography angiography (CTA), or positron
emission tomography-computed tomography (PET-CT)
New onset GCA Diagnosis of GCA made within 6 weeks of baseline visit
Relapsing/refractory GCA Diagnosis of GCA >6 weeks of baseline visit and active disease within 6 weeks of baseline visit
Active GCA
(1) At least one of the following within 6 weeks of baseline visit
(a) Unequivocal cranial symptoms of GCA (new onset localized headache, scalp or temporal artery
tenderness, ischemia-related vision loss, or otherwise unexplained mouth or jaw pain upon
mastication)
(b) Unequivocal symptoms of polymyalgia rheumatica (PMR), defined as shoulder and/or hip girdle
pain associated with inflammatory stiffness
(c) Other features judged by the clinician investigator to be consistent with GCA or PMR flares
(i.e., new or worsened extremity claudication, fever of unknown origin)
(2) And ESR ≥30 mm/hr or CRP ≥1m g / d L
Remission Absence of all symptoms attributable to active GCA and normalization of ESR (<30 mm/hr) and CRP
(<1 mg/dL)
Flare Recurrence of symptoms attributable to active GCA, with or without elevation of ESR and/or CRP
Sustained remission (SR)
(1) Absence of flare following remission by week 12 after randomization
(2) And completion of the assigned prednisone taper
(3) And not having required escape therapy at any time by week 52.
2.8.2. Short and Long Prednisone-Taper Protocols. There will
be two standardized prednisone-taper regimens: one that
extends for 26 weeks (groups A, B, and C) and the other for
52 weeks (group D) (Figure 1 and Table 3). The total duration
of prednisone therapy in each particular case will depend
on the initial dose required by the patient as judged by the
investigator at enrollment.
2.8.3. Blinding of Prednisone Treatments. The prednisone
tapers will have an open-label phase and a blinded phase
(Table 3).Prednisonedosesbetween60mgand20mgwillbe
administered in an open-label fashion. In order to prevent
unblinding due to the different taper lengths, prednisone
dosages below 20mg will be provided in numbered blister
packs for blinded administration. Depending on the patient’s
assignment to either the six- or twelve-month taper regimen,
the daily encapsulated dose may contain active prednisone,
prednisone placebo, or a combination of both.
2.9. Concomitant Immunosuppressive Medications. Concom-
itant treatment with stable doses of MTX will be allowed
only if started more than 6 weeks prior to the study
e n r o l l m e n t .Th ed o s eo fM T Xs h o u l dr e m a i ns t a b l ea n d
not be increased throughout the screening and 52 week
double-blind treatment periods. During these periods, the
MTX dose may be reduced or discontinued if necessary
f o rs a f e t yr e a s o n s ,o r ,i fi nt h eo p i n i o no ft h ei n v e s t i g a t o r ,
it is no longer required to treat the patient’s GCA. Other
immunosuppressive medications will not be allowed during
the study (Table 2).
2.10. Treatment of Flares (Escape Therapy). Patients who
cannot follow the protocol-defined prednisone taper due to
disease flare will continue in the study under an investigator-
defined open-label escape CS regimen in combination with
double-blind injections of TCZ/TCZ placebo for the full 52
weeks.Althoughthesepatientswillbedeemedasnonrespon-
ders for the primary outcome, their subsequent followup and
CS requirement will provide important information for the
analysis of secondary and exploratory endpoints.
2.11. Description of Study Assessments Efficacy Assessments.
Clinical GCA activity that will be evaluated at every study
visit include: fever (≥38
∘Co r1 0 0 . 4
∘F); symptoms of PMR;
headache; temporal artery or scalp tenderness; visual signs
or symptoms such as acute or subacute vision loss due to
arteritic anterior ischemic optic neuropathy, transient blurryInternational Journal of Rheumatology 5
Table 2: Eligibility criteria.
Inclusion criteria Exclusion criteria
(1) Diagnosis of GCA
(2) Active disease within 6 weeks of
baseline visit
(3) Willing to receive antiplatelet
therapy
(4) Willing to receive treatment for
prevention of glucocorticoid-induced
osteopenia/osteoporosis
(1) Recent or incoming major surgery
(2) Organ transplantation recipient (except corneas within 3 months prior to baseline visit)
(3) Prior treatment with any of the following:
(i) Investigational agents within 12 weeks of screening visit
(ii) Cell depleting agents (i.e., anti-CD20)
(iii) Alkylating agents including CYC
(iv) Tocilizumab
(v) HCQ, CsA, AZA, or MMF within 4 weeks of baseline
(vi) Tumor necrosis factor inhibitors within 2–8 weeks of baseline depending on the agent
(vii) Anakinra within 1 week of baseline
(viii) MTX started within 6 weeks of study enrollment
(ix) CS for other conditions other than GCA
(4) History of severe allergic reactions to monoclonal antibodies
(5) Evidence of serious uncontrolled concomitant disease (i.e., cardiovascular, respiratory, renal,
endocrine, etc.)
(6) Current liver disease that could interfere with the trial as determined by the physician
investigator
(7) History of diverticulitis, inflammatory bowel disease, or other symptomatic GI tract condition
that might predispose to bowel perforation
(8) Infections:
(i) Active current or history of recurrent bacterial, viral, fungal, mycobacterial, or other infection
(ii) Prior episode of major infection
(iii) Active TB requiring treatment within the previous 3 years
(iv) Untreated latent TB infection (LTBI)
(9) Primary or secondary immunodeficiency
(10) Malignancy (except basal and squamous cell carcinoma of the skin or carcinoma in situ of the
cervix uteri that has been excised and cured)
(11) Laboratory abnormalities: AST or ALT >1.5 × upper limit of normal (ULN), total bilirubin >
ULN, platelet count <100 × 10
9/L, hemoglobin <8.5 gr/dL, WBC count <3 × 10
9/L, ANC <2 × 10
9/L,
ALC <0.5 × 10
9/L, positive HBs antigen or positive HCV antibody
GCA: giant cell arteritis; CYC: cyclophosphamide; HCQ: hydroxychloroquine; CsA: cyclosporine A; AZA: azathioprine; MMF: mycophenolate mofetil; MTX:
methotrexate;CS:corticosteroids;TB:tuberculosis;AST:aspartateaminotransferase;ALT:alanineaminotransferase;ULN:upperlimitofnormal;WBC:white
b l o o dc e l l ;A N C :a b s o l u t en e u t r o p h i lc o u n t ;A L C :a b s o l u t el y m p h o c y t ec o u n t ;H B sa n t i g e n :h e p a t i t i sBv i r u ss u p e r fi c i a la n t i g e n ;H C V :h e p a t i t i sCv i r us.
vision,amaurosisfugax,ordiplopia;jawclaudication;newor
worsened extremity claudication; and other features judged
by the investigator to be consistent with a GCA flare.
Laboratory Assessments. Laboratory assessments to be
obtained at different timepoints will include: complete blood
counts; serum chemistry profile including renal and liver
function tests; fasting serum lipids; HbA1c; hepatitis B and C
serologies; and ESR and CRP. In order to maintain blinding,
theinvestigator/efficacyassessorwillbemaskedtotheresults
of complete blood counts, serum chemistry, ESR, and CRP.
Serological PD-PK Measures and Immunogenicity Assays.
A s s a y sd e s i g n e dt oe v a l u a t ep h a r m a c o d y n a m i ca n dp h a r m a -
cokinetic parameters of TCZ will include concentrations of
CRP, IL-6, sIL-6R, TCZ, and anti-TCZ antibodies.
Patient-Reported Outcomes. Planned patient-reported out-
comes include the patient global assessment of disease activ-
ity (PGA) using a VAS scale and the SF-36, FACIT Fatigue,
and EQ-5D questionnaires.
SafetyAssessments.Reviewofadverseevents,vitalsigns,con-
comitantmedications,andlaboratorydatawillbeperformed.
M echanismofA ctionStudies.Serum,RN A,andDN Asamples
will be collected at defined timepoints for mechanistic stud-
ies.
2.12. Outcome Measures and Study Endpoints. The efficacy
outcome measures include the assessment of disease remis-
s i o nb a s e do ns i g n sa n ds y m p t o m so fa c t i v eG C A ;E S Ra n d
CRP; adherence to the prespecified prednisone taper; the
number of flares and the time to disease flare postremission;
t h ec u m u l a t i v eC Sd o s e ;a n dp a t i e n t - r e p o r t e dq u a l i t yo fl i f e
(QoL) assessments.
The safety outcome measures include the incidence,
nature, and severity of adverse events; laboratory abnormal-
ities (i.e., cytopenias, liver function tests abnormalities, and
lipid abnormalities), and immunogenicity.
Thedefinitionoftheprimaryendpoint,SRatweek52,has
four aspects:
(1) achievement of disease remission not later than week
12 after randomization;
(2) absence of disease flare through week 52;6 International Journal of Rheumatology
Table 3: Standardized prednisone-taper protocols during GiACTA.
Weeks Daily prednisone dose
(mg) 26-week taper
Daily prednisone dose
(mg) 52-week taper
1 60 60
2 50 50
3 40 40
4 35 35
5 30 30
6 25 25
7 20 20
After week 7, the CS dosing will be double-blinded
8 15 17.5
9 12.5 17.5
10 12.5 15
11 10 15
12 91 2 . 5
13 81 0
14 71 0
15 61 0
16 61 0
17 59
18 59
19 49
20 49
21 38
22 38
23 28
24 28
25 17
26 17
27 CS placebo 7
28 CS placebo 7
29 CS placebo 6
30 CS placebo 6
31 CS placebo 6
32 CS placebo 6
33 CS placebo 5
34 CS placebo 5
35 CS placebo 5
36 CS placebo 5
37 CS placebo 4
38 CS placebo 4
39 CS placebo 4
40 CS placebo 4
41 CS placebo 3
42 CS placebo 3
43 CS placebo 3
44 CS placebo 3
45 CS placebo 2
46 CS placebo 2
Table 3: Continued.
Weeks Daily prednisone dose
(mg) 26-week taper
Daily prednisone dose
(mg) 52-week taper
47 CS placebo 2
48 CS placebo 2
49 CS placebo 1
50 CS placebo 1
51 CS placebo 1
52 CS placebo 1
(3) completionoftheassignedprednisonetaperprotocol;
(4) absence of the need for escape therapy (prednisone
increase) at any time during the 52 weeks after
randomization.
Remission is defined as the absence of signs and symptoms
attributable to GCA and normalization of ESR (<30mm/Hr)
and CRP (<1mg/dL).
Patients who do not achieve remission within 12 weeks;
donotreachaprednisonedoseofzerobythepredefinedtime
(Table 3);requireescapetherapy;orarewithdrawnearlyfrom
the study for any reason will be deemed as nonresponders in
the analysis of the primary endpoint.
2.13. Analysis
2.13.1. Efficacy Analysis. The analysis of the data will be
performed on an intention-to-treat basis, including all ran-
domized subjects.
For the primary efficacy endpoint, the TCZ treat-
ment groups will be compared to placebo (in combina-
tion with 26 weeks prednisone-taper regimen) using a
Cochran-Mantel-Haenszel test, adjusting for new onset ver-
susrefractory/relapsingdiseaseandstartingprednisonedose
(≤30mg/day, >30mg/day).
For the analysis of secondary endpoints, all continuous
endpoints such as SF-36, PGA, and cumulative CS dose will
be analyzed using a maximum likelihood repeated measures
method to compare the change from baseline to the week
52 value. The analyses will be adjusted for the stratification
factorsappliedatrandomization,aswellasthebaselinevalue
f o rt h ep a r a m e t e rb e i n gt e s t e d .Th et i m et od i s e a s efl a r e
will be analyzed using a Cox proportional hazards model
including stratification factors. The secondary endpoints will
be tested using a prespecified fixed sequence method, and
adjustmentsrequiredtocontrolformultiplicity(i.e.,multiple
dose comparisons and multiple endpoints) and to ensure that
the alpha level is maintained at 1% will be made.
Both TCZ treatment groups will be compared to the 52-
week prednisone-taper group for all the study endpoints in
an exploratory manner using the methodology as specified
previously.Furtherexploratoryanalysisconsideringvariables
such as temporal artery biopsy status, compliance with 1990
ACR versus modified diagnostic criteria, type of disease flare
(i.e.,“cranial”,“PMR”,etc.),andconcomitantMTXusewillbe
also performed.International Journal of Rheumatology 7
2.13.2. Safety Analysis. The safety analyses will include all
randomized patients who received at least one dose of study
drug. Patients will be reported according to the treatment
received.
2.14. Sample Size and Power. A sample size of 100 patients
in the A (162qw TCZ) group and 50 patients in both the B
(162q2w TCZ) and C (placebo) groups will ensure at least
90%powertodetectadifferenceintheproportionofpatients
in sustained remission at week 52 for both TCZ arms versus
placebo at an alpha level of 0.01 (2 sided). This assumes that
the absolute difference in the proportion of patients who are
in sustained remission at 52 weeks is equal to 40% (assuming
𝜌6-TCZ =7 0 %v e r s u s𝜌6-mCS = 30%). In addition, 50 patients
will be included in the 52-week prednisone-tapering group
(D).
Although a difference might still be identified, it should
be noted that our study will not be powered to find a
statistically significant difference between the TCZ arms and
the 52-week prednisone-tapering arm (group D). However,
we anticipate that data from patients in this fourth arm will
provide valuable information regarding the optimal dosing
regimens of CS in GCA and help evaluate the risk-benefit
ratio of TCZ as a CS-sparing agent.
2.15. Data and Safety Monitoring. An independent Data and
Safety Monitoring Board (DSMB) plans to review accumu-
lateddataonsafetyandefficacy atleast twiceayearand/orin
an event-driven fashion as necessary.
2.16.MechanisticSubstudy. Peripheralbloodwillbecollected
at different timepoints to evaluate the impact of anti-IL-
6R therapy on the concentrations of selected cytokines and
chemokines. Genome-wide mRNA expression profiling will
be done at baseline and 12 months.
3. Discussion
The current standard of care for GCA, CS therapy, is a
suboptimal treatment strategy. A high percentage of patients
relapse upon weaning treatment and more than 85% of
the patients suffer from CS-related side effects [7, 12, 14,
15, 44]. Persistently active vascular inflammation despite
ongoingCStherapyhasbeendemonstratedinanimalmodels
[32, 50] and confirmed in patients who lack overt clinical
symptoms [51–53]. In addition, up to a quarter of all cases
experience complications from large vessel inflammation
(i.e., aneurysm) despite treatment with CS [53–56]. Thus, an
unmet need exists in GCA for better and less toxic treatment
alternatives. GiACTA will explore the hypothesis that TCZ is
effective in maintaining GCA remissions and sparing CS.
Controlled studies in GCA must address several chal-
lenges. First, although management guidelines have been
c r e a t e df o rl a r g e - v e s s e lv a s c u l i t i sa n dG C A[ 57, 58], the
absence of standardization for CS therapy creates difficulties
when comparing a new treatment approach. Second, the
high morbidity burden related to GCA argues in favor of
designing trials with endpoints that reflect clinically mean-
ingful outcomes and justify the use of newer, sometimes
expensive therapies. Third, since the development of the
ACR classification criteria for GCA [59], rheumatology has
incorporatednew imagingmodalitiesthatoften complement
the diagnostic process of GCA (US, CTA, MRI/MRA, and
PET-CT) [60]. For this reason, some patients currently
diagnosed in clinical practice may not be captured by the
1990criteria[61].M o r eo v er ,themec ha nismo factio no fT CZ
creates specific problems that need to be considered ap r i o r i
in order to prevent the unblinding of treatments that some
expectedlaboratorychangescouldgenerate.Finally,although
requiring a masked prednisone-taper phase that begins once
patients reach 20mg/day creates certain logistical challenges,
thisnecessityhasledtoanoveltrialdesignthatwillaccurately
assess the potential of TCZ for exerting CS-sparing effects in
this disease. We address these issues, one by one.
3.1. Defining the Standard of Care for Corticosteroid Use.
Large vessel vasculitis (LVV) guidelines address the initial
CS dose but do not standardize the rate of tapering in GCA
[57]. The approach to treatment varies significantly among
physicians.Asageneralruleinusualclinicalpractice,anewly
diagnosed patient initially receives the equivalent of approx-
imately 1mg/kg of prednisone daily (≈60mg/day). This dose
is given until the reversible manifestations of the disease
abate and the inflammatory markers normalize (≈4 weeks).
The dose is then gradually tapered to reach a maintenance
of 10mg/day by 2.5–6 months, and 5 to 0mg/day by 12–
24 months (and sometimes longer) [5, 8]. Subjects already
carrying the diagnosis of GCA whose symptoms recur upon
CS tapering (relapsing/refractory GCA) typically receive a
dose of 10mg above the last dose that was able to control
the disease, unless the severity of the flare warrants higher
d o s e s( e . g . ,t h r e a t e n e dv i s i o nl o s s ) .F o l l o w i n gc o n t r o lo ft h e
activity, a tapering regimen of variable length is instituted.
The median cumulative CS dose of an American cohort of
GCA patients followed for 10 years was 7.4grams (mean
daily dose 13.6mg/day). This treatment led to significant CS-
induced toxicity, yet was associated with a relapse rate of
48% [7]. More recently, a relapse rate of 40.8% and mean
cumulative CS doses of 12.5 grams were demonstrated in a
population-based study from Northwestern Spain [62].
In contrast to the variability of clinical practice that
often leads to CS use extending over years, clinical trials
have frequently used tapers over a period of six months.
Unfortunately, the investigational agents employed to date in
thesestudieshavenotbeensuccessfulinreducingthenumber
of disease flares in a meaningful manner, and annual relapse
r a t e si ns o m et r i a l sh a v eb e e na sh i g ha s8 0 %[ 14, 15].
To address the problem of variability in the standard of
care, GiACTA will use two prednisone-tapering regimens
as control arms. The six-month taper was created for the
efficacy analysis, to test the ability of TCZ to maintain
disease remission and spare CS. Since many patients in the
course of usual care receive courses that are longer than
six months, we will also enroll patients into a comparative
12-month prednisone-tapering arm (group D). It should
be noted that the study will not be powered to find a
statistically significant difference between the TCZ arms and
the 12-month prednisone-tapering arm, but this group will8 International Journal of Rheumatology
provide substantial information on the natural history of CS-
treated disease and serve for exploratory analysis. To prevent
unmasking due to the different tapering protocols, both the
patients and investigators will be blinded to the dose of
prednisone given after the daily dose has been reduced to
2 0m g / d a y( w e e k7 )t h r o u g ht h ee n do fP a r t1( w e e k5 2 ) .
3.2. Identification of Clinically Meaningful Endpoints. The
ideal agent for a chronic immune-mediated disease would
restore tolerance and induce drug-free remissions following
treatment. More realistically, a useful agent for GCA should
be able to maintain disease remission, while decreasing the
toxicity associated with CS therapy. CS-free sustained remis-
sion at 52 weeks, cumulative CS dose, CS-related AEs, CS-
TCZ-free sustained remission, and quality of life measures
comprise a set of meaningful endpoints that will rigorously
test the efficacy of TCZ in GCA. Furthermore, assuming
an absolute treatment effect difference of 40% between the
experimental and the control groups, and setting the alpha
level at 0.01 for the analysis of the primary endpoint will
assure robustness of the results if the trial meets its primary
outcome.
3.3. GCA Diagnostic Criteria. We anticipate that the vast
majority of subjects enrolled in GiACTA will meet the
ACR 1990 classification criteria for the diagnosis of GCA
[59]. However, as progress has been made in understanding
the pathology of the disease and new vascular imaging
m o d a l i t i e sh a v ee m e r g e ds i n c e1 9 9 0 ,w eh a v ec r e a t e dr e v i s e d
diagnostic criteria that are consistent with current clinical
practice and consider the presence of evidence of large vessel
vasculitisincross-sectionalimaging(MRA,CTA,PET-CT,or
angiography) an important diagnostic feature. Because these
radiologic tests have not yet been validated for the diagnosis
of GCA, the results using this approach will be interpreted
with caution, and we will perform a sensitivity analysis to
evaluate the study outcomes in patients meeting the ACR
classification criteria versus the overall study population.
3.4. Prevention of Unblinding. To prevent unblinding due
to expected rapid normalization of inflammatory mark-
ers or the occurrence of specific laboratory abnormalities
sometimes observed during TCZ therapy (e.g., neutropenia,
transaminase elevation), a safety assessor independent of the
investigator/efficacy assessor will monitor the results of the
following laboratory parameters: ESR, CRP, total white blood
cell count (WBC), absolute neutrophil count (ANC), platelet
counts, and aspartate aminotransferase (AST) and alanine
aminotransferase (ALT) concentrations. The safety assessor
will determine the indication for dose modification of TCZ
(or TCZ placebo) following guidelines and risk mitigation
strategies used for TCZ in the RA studies.
We have considered the possibility that blinding the
investigatorstothelevelsofacutephasereactantscouldcreate
problems during the longitudinal follow-up, since many
clinicians rely at least in part on levels of these markers as
guidestothedegreeofongoinginflammation.Asanexample,
the ESR and CRP values may help in differentiating non-
specific musculoskeletal pain from a flare of PMR during CS
dose reduction. However, the levels of acute phase reactants
canbemisleading,withbothfalse-negativeandfalse-positive
results. Overtreatment with CS following excessive emphasis
on the values of inflammatory markers places patients at
risk for additional CS-related morbidity. For this reason,
once patients are enrolled, only clearly defined signs and
symptoms will be used as parameters of disease activity, and
only investigators with expertise in the care of patients with
GCA will participate.
3.5. Prednisone Blinding. To our knowledge, this is the
first clinical trial in any disease to incorporate blinded CS
regimens into its design. This strategy, which will permit an
unbiased evaluation of the CS-sparing effects of TCZ, may be
extrapolated to trials in other immune-mediated conditions,
thereby helping to address an important need in the area of
inflammation.
3.6. Exploratory Analyses. Thelargesttrialperformedtodate
in GCA offers important opportunities for exploratory sub-
studies.Inthisregard,analyzingtheeffectthatIL-6signaling
blockade has on different components of the Th1, Th17 and
Treg pathways may elucidate the mechanisms of action of
TCZ and increase the understanding of the immunopatho-
genesis of this disease. Moreover, genome-wide transcrip-
tome analysis may identify important pathogenic factors,
n e wb i o m a r k e r s ,a n dg e n es i g n a t u r e sa s s o c i a t e dw i t hc r i t i c a l
clinical outcomes (e.g., relapse risk, response to therapy, and
others).
4. Conclusion
In summary, the GiACTA study will assess the safety and
efficacy of TCZ for the treatment of GCA. The use of CS dose
blinding is unique in the field of clinical trials of immune-
mediateddiseaseandmaybeextendedtootherinvestigations
inwhichtheidentificationofaCS-sparingagentisimportant.
Successful achievement of the primary outcome in this trial
wouldmarkthefirst demonstrationofaneffectivealternative
to continuous CS use as a strategy for maintaining remission
in GCA.
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